TY - JOUR
T1 - Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4
AU - Watford, Wendy T.
AU - Hissong, Bruce D.
AU - Bream, Jay H.
AU - Kanno, Yuka
AU - Muul, Linda
AU - O'Shea, John J.
PY - 2004/12
Y1 - 2004/12
N2 - Produced in response to a variety of pathogenic organisms, interleukin (IL)-12 and IL-23 are key immunoregulatory cytokines that coordinate innate and adaptive immune responses. These dimeric cytokines share a subunit, designated p40, and bind to a common receptor chain, IL-12Rβ1. The receptor for IL-12 is composed of IL-12Rβ1 and IL-12Rβ2, whereas IL-23 binds to a receptor composed of IL-12Rβ1 and IL-23R. Both cytokines activate the Janus kinases Tyk2 and Jak2, the transcription factor signal transducer and activator of transcription 4 (STAT4), as well as other STATs. A major action of IL-12 is to promote the differentiation of naïve CD4+ T cells into T-helper (Th) 1 cells, which produce interferon (IFN)-γ, and deficiency of IL-12, IL-12R subunits or STAT4 is similar in many respects. In contrast, IL-23 promotes end-stage inflammation. Targeting IL-12, IL-23, and their downstream signaling elements would therefore be logical strategies for the treatment of immune-mediated diseases.
AB - Produced in response to a variety of pathogenic organisms, interleukin (IL)-12 and IL-23 are key immunoregulatory cytokines that coordinate innate and adaptive immune responses. These dimeric cytokines share a subunit, designated p40, and bind to a common receptor chain, IL-12Rβ1. The receptor for IL-12 is composed of IL-12Rβ1 and IL-12Rβ2, whereas IL-23 binds to a receptor composed of IL-12Rβ1 and IL-23R. Both cytokines activate the Janus kinases Tyk2 and Jak2, the transcription factor signal transducer and activator of transcription 4 (STAT4), as well as other STATs. A major action of IL-12 is to promote the differentiation of naïve CD4+ T cells into T-helper (Th) 1 cells, which produce interferon (IFN)-γ, and deficiency of IL-12, IL-12R subunits or STAT4 is similar in many respects. In contrast, IL-23 promotes end-stage inflammation. Targeting IL-12, IL-23, and their downstream signaling elements would therefore be logical strategies for the treatment of immune-mediated diseases.
UR - http://www.scopus.com/inward/record.url?scp=9644257195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9644257195&partnerID=8YFLogxK
U2 - 10.1111/j.0105-2896.2004.00211.x
DO - 10.1111/j.0105-2896.2004.00211.x
M3 - Review article
C2 - 15546391
AN - SCOPUS:9644257195
SN - 0105-2896
VL - 202
SP - 139
EP - 156
JO - Immunological Reviews
JF - Immunological Reviews
ER -